Why Minerva Neurosciences, Inc.’s (NERV) Stock Is Up 5.60%
As of Tuesday, October 20, Minerva Neurosciences, Inc.’s NERV share price has surged by 5.60%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Commentary & Analysis
Why Minerva Neurosciences, Inc.’s (NERV) Stock Is Up 5.11%
As of Monday, October 19, Minerva Neurosciences, Inc.’s NERV share price has surged by 5.11%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Minerva Neurosciences, Inc.’s (NERV) Stock Is Down 7.26%
As of Tuesday, October 13, Minerva Neurosciences, Inc.’s NERV share price has dipped by 7.26%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Minerva Neurosciences, Inc.’s (NERV) Stock Is Down 10.02%
As of Tuesday, October 13, Minerva Neurosciences, Inc.’s NERV share price has dipped by 10.02%, which has investors questioning if this is right time to buy.Tudor Pop
Why Minerva Neurosciences, Inc.’s (NERV) Stock Is Down 5.03%
As of Monday, October 12, Minerva Neurosciences, Inc.’s NERV share price has dipped by 5.03%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | NERV | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $120.3 | $228.4 | 24% |
|
| Shares Out (Mil) | 79.1 | 53.9 | 58% |
|
| Institutional Ownership | 99.1% | 92.9% | 85% |
|
| Float (Mil) | 34.3 | 41.7 | 38% |
|
| Beta | -0.10 | 0.95 | 4% |
|
| Avg Daily Volume (000s) | 152 | 582 | 41% |
|
| Price Change (52-week) |
1.2% | 47.6% | 53% |
|
| Growth | NERV | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (174.7%) | (10.1%) | 0% |
|
| EPS (5yr) | (147.7%) | 15.8% | 0 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 56.4% | (15.7%) | 94% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | 1 | 1 | |
| Current EPS | ($0.180) | ($0.570) | ($0.420) | |
| Month Ago EPS | na | ($0.570) | ($0.420) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.010) | ($0.200) | na | |
| Year/Year Chg | 30.4% | (98.4%) | (99.6%) | |
| Financials | NERV | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($394) | ($44) | 4% |
|
| EPS (TTM) | ($14.441) | ($1.500) | 3% |
|
| Operating Cash Flow (TTM) (Mil) | ($26) | ($33) | 13% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $60 | $4 | 40% |
|
| Enterprise Value (Q1) (Mil) | $171 | $177 | 25% |
|
| Valuation | NERV | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.19 | na |
|
| P/E | na | 19.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | NERV | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (73.7%) | na |
|
| ROA | (628.4%) | (47.1%) | 0% |
|
| ROE | 321.4% | (54.1%) | 99% |
|
| Liabilities to Assets | 312.0% | 29.1% | 100% |
|
| F-Score | 2 | 2 | na |
|
Minerva Neurosciences, Inc. did not pass any screens on 10/20/2026.
